Clinical Trial Update: Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ceftolozane-tazobactam to meropenem for ESBL/AmpC-producing Enterobacterales bacteremia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Bloodstream Infection

Drugs mentioned

• Ceftolozane/Tazobactam (ceftolozane/tazobactam)
• Meropenem (Meropenem)

Snippet

Sponsor: The University of Queensland | Conditions: Bacteremia Caused by Gram-Negative Bacteria | Phase 3 | Status: WITHDRAWN